UPDATE: LiveOne (Nasdaq: LVO) to Present Business Update at Trump Mar-a-Lago Today
Highlighting a 55% Increase in Tesla Users, Now Over 700K+ Since Jan. 1st- Including 350K+ Ad-Supported Tesla Users- $40+M in New B2B ...
Celebrating 40 Years of the Nasdaq-100 Index® (NDX®)
The combined value of all investment products tracking the NDX® ecosystem globally exceeds $500 billion94 Exchange Traded Products track NDX® in ...
LiveOne (Nasdaq: LVO) to Present Business Update at Trump Mar-O-Lago Today
Highlighting a 55% Increase in Tesla Users, Now Over 700K+ Since Jan. 1st- Including 350K+ Ad-Supported Tesla Users- $40+M in New B2B ...
Helport AI Opens Office in the Philippines
New ‘Global Center of Excellence’ to Drive Artificial Intelligence Operations and Service Offerings in the Business Process ...
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
Immutep Quarterly Activities Report Q2 FY25
Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...
Ryoncil® Commercial Launch Update and Product Pipeline
FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Atossa is also announcing the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, “Sustained Release Compositions of Endoxifen.” The 31 claims of this new patent are ...
Pacira Announces Updates to Board of Directors
Accomplished Business and Financial Leader, Laura Brege, Appointed Chair ---- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of ...
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...
Aduro Clean Technologies Files New Patent Application on Novel Process Design
Aduro Clean Technologies Inc. (“ Aduro ” or the “ Company ”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5 ), a clean technology ...
Coda Octopus Group Reports Fiscal 2024 Financial Results
Coda Octopus Group, Inc. (Nasdaq: CODA) today reported its audited financial results for its fiscal year ended October 31, 2024 (FY2024). Annmarie Gayle, CODA’s Chairman and CEO, commented: “I am ...